Our source register
Return to the document.
These records support specific statements. Their presence does not supply a missing prescription label, completed transaction or observed patient outcome. Read the source type and its date alongside the article.
Provider product description · Checked 2026-09-27
CoreAge Rx: Tirzepatide Microdosing Therapy
Read the original document ↗Articles citing this record
Provider offer; fresh direct HTML supplies complete cards and footer · Checked 2026-09-27
CoreAge Rx: Shared microdose offer and qualifications
Read the original document ↗Articles citing this record
Current exact approved-product labeling · Checked 2026-09-27
Zepbound prescribing information, revised August 2026
Read the original document ↗Articles citing this record
- CoreAge Rx tirzepatide microdosing: documented, inferred and unresolved
- Tirzepatide program records compared: what the documents actually establish
- Ivím tirzepatide records review: the product page is only one part
- Noom tirzepatide Microdose records review: names, footnotes and unresolved details
- What a tirzepatide adverse-event report can—and cannot—tell you
- A tirzepatide trial regimen is more than an ingredient name
Current exact approved-product labeling · Checked 2026-09-27
Mounjaro prescribing information, revised August 2026
Read the original document ↗Articles citing this record
Regulatory safety communication · Checked 2026-09-27
FDA: Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
Read the original document ↗Articles citing this record
- CoreAge Rx tirzepatide microdosing: documented, inferred and unresolved
- Tirzepatide program records compared: what the documents actually establish
- Ivím tirzepatide records review: the product page is only one part
- Noom tirzepatide Microdose records review: names, footnotes and unresolved details
- Compounded tirzepatide: which record answers which question?
- What a tirzepatide adverse-event report can—and cannot—tell you
Regulatory product-status explanation · Checked 2026-09-27
FDA: Compounding and the FDA, Questions and Answers
Read the original document ↗Articles citing this record
- CoreAge Rx tirzepatide microdosing: documented, inferred and unresolved
- Tirzepatide program records compared: what the documents actually establish
- Ivím tirzepatide records review: the product page is only one part
- Noom tirzepatide Microdose records review: names, footnotes and unresolved details
- Compounded tirzepatide: which record answers which question?
Provider product and price description · Checked 2026-09-27
Ivím Health: GLP-1 Microdosing
Read the original document ↗Articles citing this record
Provider service terms; not an individual legal determination · Checked 2026-09-27
Ivím Health: Terms and Conditions, effective May 27, 2026
Read the original document ↗Articles citing this record
Provider membership and payment terms · Checked 2026-09-27
Ivím Health: Membership Agreement
Read the original document ↗Articles citing this record
Provider policy and cross-referenced terms · Checked 2026-09-27
Ivím Health: Return and Refund Policy
Read the original document ↗Articles citing this record
Provider program identity and availability · Checked 2026-09-27
Noom: Microdose GLP-1Rx Plus Program
Read the original document ↗Articles citing this record
Provider care, promotion and offer qualifications · Checked 2026-09-27
Noom: Shared Microdose GLP-1Rx offer
Read the original document ↗Articles citing this record
Provider named-program pricing · Checked 2026-09-27
Noom: 2026 cost explanation, updated September 22, 2026
Read the original document ↗Articles citing this record
Provider catalog and reported-outcome limitations · Checked 2026-09-27
Noom: Medication programs and pricing directory
Read the original document ↗Articles citing this record
Provider program-specific refund policy · Checked 2026-09-27
Noom: Refund Policy
Read the original document ↗Articles citing this record
Regulator pharmacy-record guidance · Checked 2026-09-27
FDA: Locate a State-Licensed Online Pharmacy
Read the original document ↗Articles citing this record
Regulator explanation of safety-report limitations · Checked 2026-09-27
FDA: Adverse Event Monitoring System Public Dashboard
Read the original document ↗Articles citing this record
Primary reporting-system documentation · Checked 2026-09-27
FDA: Drug Adverse Event Overview
Read the original document ↗Articles citing this record
Full primary randomized-withdrawal trial paper, first published December 2023 · Checked 2026-09-27